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Despite recent advances in techniques of reperfusion for acute myocardial 
ischemia, myocardial salvage remains suboptimal. /]-Blockers have been 
shown to limit infarct size during acute ischemia, but their negative 
inotropic properties have limited their use. Cardiopulmonary bypass is an 
attractive technique for cardiac resuscitation because it can stabilize a 
hemodynamically compromised patient and potentially reduce myocardial 
oxygen consumption. In an attempt to maximize myocardial salvage in the 
setting of acute ischemia, the combination of esmolol, an ultrashort-acting 
E-blocker, with percutaneous cardiopulmonary bypass was evaluated. Four 
groups of instrumented dogs underwent 2 hours of myocardial ischemia 
induced by occlusion of the proximal left anterior descending coronary 
artery, followed by 1 hour of reperfusion. Throughout the period of 
ischemia and reperfusion, esmolol plus percutaneous cardiopulmonary 
bypass was compared with esmolol alone, percutaneous cardiopulmonary 
bypass alone, and control conditions. After the reperfusion period, the 
extent of infarction of the left ventricle at risk was determined. Four 
animals had intractable arrhythmias: one in the esmolol plus bypass group, 
one in the esmolol group, and two in the control group. The extent of 
infarction of the left ventricle at risk was significantly reduced in the 
esmolol plus bypass group (30%) compared with bypass alone (52%), with 
esmolol alone (54%), and with the control groups (59%; p < 0.05). We 
conclude that in this experimental model the combination of esmolol with 
bypass improves myocardial salvage after ischemia and reperfusion. 
(J Thorac Cardiovasc Surg 1996;111:1085-91) 
R ecent advances in surgical, pharmacologic, and interventional techniques have made rapid 
reperfusion achievable in the setting of acute myo- 
cardial ischemia. Myocardial salvage is frequently 
suboptimal with even short periods of ischemia, 
however, resulting in significant myocardial injury. 
There are several reported strategies to improve 
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myocardial salvage, including percutaneous cardio- 
pulmonary bypass, infusion of/3-blockers, and in- 
traaortic balloon counterpulsation, but none has 
been shown to be uniformly effective. 1-6 Consider- 
able clinical and experimental evidence has demon- 
strated that/3-blockers can attenuate the extent of 
myocardial injury during ischemia and reperfu- 
sion. 5-12 Their utility, however, is limited by their 
negative inotropic properties. Esmolol, an ultra- 
short-acting ¢3-blocker, is an attractive agent be- 
cause its short half-life allows its negative inotropic 
effects to be rapidly eliminated minutes after the 
infusion is stopped. 
There is considerable interest in the use of car- 
diopulmonary bypass for resuscitation of patients 
with cardiac decompensation after failed percutane- 
ous transluminal coronary angioplasty and acute 
myocardial infarctionJ 3-18 Cardiopulmonary b pass 
decreases myocardial oxygen consumption (MV02) 
by decreasing afterload and is highly effective at 
maintaining hemodynamic stability and resuscitat- 
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ing patients. <16 The combinat ion of cardiopulmo- 
nary bypass with esmolol is attractive because it 
allows the use of /3-blockade in situations of hemo- 
dynamic instability, where it would not be otherwise 
possible. The aim of this exper imental  study was to 
evaluate the effectiveness of the combinat ion of 
card iopulmonary support with esmolol to reduce the 
extent of infarction. 
Methods and materials 
All of the experiments were conducted according to the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the National Institute of Laboratory Animal 
Resources and published by the National Institutes of 
Health (NIH Publication No. 86-23, revised 1985). Sixteen 
conditioned mongrel dogs in good health and weighing 
more than 35 kg were anesthetized and maintained with 
an intravenous infusion of sodium pentobarbital. In the 
supine position, the animals were intubated with 8 mm 
cuffed endotracheal tubes and ventilated with volume- 
cycled respirators (Harvard Apparatus, Inc., Memphis, 
Mass.), initially at a rate of 15 cycles/rain and a tidal 
volume of 15 ml/kg and then adjusted according to the 
arterial blood gases. Electrocardiogram and temperature 
were continuously displayed and recorded (Gould Pres- 
sure Recorder, model 2400S; Gould Inc., Test and Mea- 
surement Recording Systems Division, Cleveland, Ohio). 
A Swan-Ganz catheter (American Edwards Laboratories, 
Santa Ana, Calif.) was inserted through the right jugular 
vein. A midsternotomy incision was made, and the peri- 
cardium was opened and suspended to the chest wall. The 
left anterior descending coronary artery was identified and 
encircled proximal to the first diagonal branch with a large 
silk tie. The animals were anticoagulated with 3 mg/kg 
heparin. 
Experimental design. The animals were subdivided 
into four treatment groups. In the control group (C), the 
animals underwent 2 hours of myocardial ischemia by 
occlusion of the left anterior descending coronary artery, 
followed by 1 hour of reperfusion. At the end of the 
reperfusion period, the animals were killed and under- 
went infarct analysis. In the esmolol group (E), the 
animals underwent a similar period of myocardial isch- 
emia and in addition received an infusion of 250 mg • 
kg 1 . min- i  esmolol throughout the myocardial isch- 
emic period, beginning 15 minutes before the ligation of 
the left anterior descending coronary artery, and 125 mg • 
kg -~ min ~ during the reperfusion period. In the 
cardiopulmonary bypass group (B), the animals were 
started and maintained on bypass throughout the ischemic 
period and for 30 minutes of reperfusion and were then 
weaned from bypass. In the esmolol plus cardiopulmonary 
bypass group (EB), the animals were given the esmolol as 
in the E group and were placed on bypass as in the B 
group. Treatment modalities (esmolol infusion, bypass, or 
both) were started 15 minutes before ligation of the left 
anterior descending coronary artery in an attempt o 
mimic the clinical scenario of a patient with unstable 
hemodynamics after unsucessful percutaneous translumi- 
nal coronary angioplasty or a developing myocardial in- 
farction. 
Cardiopulmonary support. The left femoral vessels 
were exposed and a 22F heparin-coated percutaneous 
venous cannula (Cook Incorporated, Bloomington, Ind.) 
was inserted over a guidewire. The tip of the venous 
cannula was positioned at the superior cavoatrial junction. 
The femoral artery was exposed and cannulated irectly 
with an 18F percutaneous arterial cannula (Cook). The 
arterial and venous lines were connected to a perfusion 
circuit that used a Bio-Medicus BP-80 (Bio-Medicus, Inc., 
Minneapolis, Minn.) centrifugal pump and Bently BCM 7 
oxygenator (Bently Laboratories, Inc., Irvine, Calif:). The 
circuit was primed with lactated Ringer's olution (Abbott 
Laboratories, North Chicago, Ill.). Animals were placed 
on normothermic percutaneous cardiopulmonary b pass 
at a flow equivalent to a calculated index of 2.2 L • min • 
m -. 
Infarct analysis. At the conclusion of the reperfusion 
period, the animals underwent analysis of infarct size. The 
left anterior descending coronary artery was resnared, and 
5 ml/kg of 1% gentian violet was injected into the left 
atrium. The heart was excised, and the left ventricle was 
frozen at -20  ° C for 20 minutes. The ventricle was then 
sliced in 3 mm sections, starting at the apex. The slices 
were then incubated for 15 minutes at 37 ° C and stained 
with 2,3,5-triphenyl-2H-tetrazolium chloride. The myo- 
cardial slices were reincubated and fixed in 10% formalin. 
The outlines of the left ventricle, infarcted tissue, normal 
tissue, and area at risk were traced onto acetate. Areas of 
interest were calculated from the acetate tracings with a 
digital planimetry board, and ratios of area of infarct to 
area at risk (AI/AR) were calculated. The method of 
staining to delineate the necrotic tissue from ishemic 
tissue is a well-accepted, commonly used technique.~ 9 The 
chemical used (2,3,5-triphenyl-2H-tetrazolium chloride) 
stains normal tissue containing dehydrogenase enzymes 
brick red. Infarcted tissue, depleted of these enzymes, 
remains pale yellow. Tissue samples from infarcted, at- 
risk, and normal areas of the left ventricle from each 
animal were collected for routine histopathologic exami- 
nation. 
Statistical analysis. Significant differences in AI/AR 
ratios for the four groups were determined by two-way 
analysis of variance. Post hoc analysis was completed with 
the Student-Newman-Keuls te t, and data were consid- 
ered significant forp < 0,05. Differences in heart rate and 
mean arterial pressure for each respective group were 
evaluated at each time interval for the four groups by 
one-way analysis of variance with post hoc analysis com- 
pleted with the Student-Newman-Keuls test. Data are 
presented as mean +_ SEM. 
Results 
Infarct analysis results are summarized in Table I. 
Area  at risk for infarction and area of infarction did 
not differ significantly within each group for the 
animals that survived beyond the 30-minute reper- 
fusion per iod and for those that died at between 30 
and 60 minutes of reperfusion. The area at risk for 
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infarction for each group ranged from 36.2% to 42% 
of the left ventricle and did not significantly differ 
between groups. Group C had an AI/AR ratio of 
59.1% _+ 4.9%, whereas groups E and B had AI/AR 
ratios of 53.8% _+ 1.3% and 51.7% + 4.0%, respec- 
tively. Group EB exhibited an AI/AR ratio reduced 
by approximately one half to 29.6% _+ 7.6% (p < 
0.05). Normalized heart rates, shown in Fig. 1, were 
lowest at 60 minutes in group E (p < 0.05) com- 
pared with the control group and highest at 30 
minutes after reperfusion in group B (p < 0.001) 
compared with the control group. Mean arterial 
pressure (Fig. 2) did not change significantly during 
the procedure for any groups. 
Heart rate and mean arterial pressure are pre- 
sented in Table II. The parameter of greatest im- 
portance was the AI/AR ratio; heart rate and mean 
blood pressure data, however, provided subtle but 
independent evidence to reinforce the efficacy of 
combining esmolol with bypass. Histopathologic ex- 
amination of hematoxylin and eosin-stained tissue 
sections confirmed that the infarct analysis was 
valid. The general arrangement of myocytes in the 
infarcted areas was disturbed, with edema and in- 
creased extracellular spaces. The myocytes were 
slightly swollen and had disrupted membranes. The 
association of myocytes was loosened, and leuko- 
cytic infiltration was present. In the area at risk 
there was little evidence of myocardial damage in 
some noninfarcted portions. 
Discussion 
Recent strategies to treat acute myocardial isch- 
emic events have focused on methods of directly 
reversing the ischemic state by eliminating the ob- 
struction to blood flow through the use thrombolytic 
agents, surgery, and angioplasty. Despite these ad- 
vances in techniques of reperfusion for acute myo- 
cardial ischemia, myocardial salvage remains ubop- 
timal, la-18 It is unclear why short periods of ischemia 
followed by rapid reperfusion are not associated 
with myocardial salvage but rather end in infarction. 
In an attempt o reduce the extent of infarction 
associated with ischemia, several strategies have 
been clinically and experimentally investigated. One 
of the most promising areas of research into the 
modulation of the response to ischemia is through 
/3-blockade. 
The /3-blockers have demonstrated a beneficial 
effect in reducing myocardial damage in the setting 
of acute ischemia in both clinical and experimental 
studies; the mechanism through which this occurs, 
Table I. Comparison of extent of infarction between 
groups 
AI (%) AR (%) AI/AR (%) 
Contro l  21.6 ± 2.7 36.2 ± 1.9 59.1 ± 4.9 
EsmoloI  19.9 + 3.7 37.3 _+ 8.4 53.8 _+ 1.3 
Bypass 21.8 _+ 2.8 42.0 _+ 4.5 51.7 _+ 4.0 
Esmolo l  and  bypass 12.5 + 4.2 39.8 + 3.8 29.6 _+ 7.6* 
Values are mean _+ standard error of the mean. A/, Area of left ventricle 
infarcted; AR, area of left ventricle at risk. 
*p < 0.05; significantly different from control, esmolol, and bypass. 
however, is not yet completely understood. Several 
theories have been postulated regarding the protec- 
tive nature of/3-blockers, including that they exhibit 
their protective ffect by decreasing myocardial met- 
abolic requirements during the ischemic event, that 
they increase the coronary blood flow and therefore 
oxygen delivery to the ischemic tissue during or after 
the ischemic event, 18'2° and that they render the 
myocardium ore resist~nt to the effects of isch- 
emia. 21-23 The /3-blockers have been shown to re- 
duce the myocardial metabolic requirements through 
both indirect hemodynamic effects and direct cellu- 
lar effects. The /3-blockers indirectly reduce the 
energy requirements bydecreasing heart rate, mean 
arterial pressure, contractile state, and the tension 
development in the ventricle, thus reducing the 
pressure-related work of the heart. 2426 This reduc- 
tion in work can be seen as a reduction in MVo 2 and 
correlates closely with the left ventricular systolic 
pressure-volume area, which has also been shown to 
decrease. 27
In addition to the indirect hemodynamic effect of 
/3-blockade, /J-blockers can reduce mitochondrial 
respiration by inhibition of reduced nicotinamide 
adenine dinucleotide phosphate oxidase, 28 inhibit 
calcium uptake by isolated sarcoplasmic reticulum, 29
and protect he sarcolemma from ischemic injury. 3° 
These direct cellular changes decrease contractile 
state, myocardial work, and energy requirements. It 
has also been demonstrated that /3-blockers have 
several effects on myocardial substrate metabolism. 
There is evidence that during ischemia,/~-blockade 
renders the heart less dependent on the use of free 
fatty acids and more dependent on carbohydrates as 
metabolic fuel aa' 29" 31' 32 and in addition inhibits 
phosphorylase activity. 33 What specific effects these 
alterations in metabolic activity have on reperfusion 
injury remains unclear. Furthermore, the cardiopro- 
tective nature of/3-blockade may reside in the ability 
of/3-b!ockers to reduce free radical-mediated inju- 
ry.34 Ischemic myocardium treated with esmolol has 
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Fig. 1. Percentage change in heart rate as a function of baseline values during ischemia nd reperfusion. +, p < 0.05 vs 
control by analysis of variance; #, p < 0.001 vs control by analysis of variance. 
been shown to have lower levels of lipid peroxida- 
tion, a marker of myocardial membrane injury, than 
seen in untreated regions of the left ventricle. 9 
We chose to use esmolol, an ultrashort-acting 
agent, because of its clinical safety. The safety of this 
agent is due not only to the rapid reversibility of its 
effects with discontinuation of administration but 
also to the ease of titration of action, which allows 
rapid adjustment to meet changing patient needs. 
This is particularly useful in patients with myocar- 
dial ischemia, for whom optimizing the oxygen 
supply-demand ratio is essential but among whom 
heart failure, conduction abnormalities, and hypo- 
tension are frequent clinical problems. Despite the 
potential benefits, the use of /3-blockers in the 
setting of acute ischemia is limited by their inherent 
negative inotropic nature. In addition, the hemody- 
namic status during periods of ischemia may already 
be tenuous and thus preclude the use of/3-blockers. 
In an effort to overcome these limitations, we at- 
tempted to support the systemic irculation with 
cardiopulmonary b pass while administering/3-block- 
ers. Another potential benefit of cardiopulmonary 
bypass is that it treats the hemodynamic instability 
associated with ischemic myocardial failure, promoting 
hemodynamic stabilization and whole-body resuscita- 
tion. 5 Other agents have been used in an attempt to 
improve postbypass left ventricular function. Additives 
or substrates have typically been combined with car- 
diopulmonary bypass in the setting of acute ischemia. 
These include metabolic substrates such as glutamate 
or aspartate, 35'36 oxygen free-radical scavengers, 37 and 
nitric oxide donors such as L-arginine. 3s Significant 
reductions in myocardial injury have been acheived 
with flee-radical scavengers and nitric oxide donors. 
Although these agents have been shown to improve 
postreperfusion left ventricular function, they have not 
been uniformly successful in all models of ischemia- 
repeffusion because of several factors. For an additive 
to be useful in the majority of experimental nd 
clinical studies, the additive must be able to prevent to 
some degree myocardial oxidative stress, to prevent 
ischemic injury to the myocytes and endothelial cells, 
or to protect he myocardium from reperfusion i jury. 
An additive that can meet hese requirements has not 
yet been found. Nonetheless, although the exact mech- 
anism through which esmolol protects the myocar- 
dium from reperfusion i jury or decreases infarct size 
remains unknown, it is clear that a cardioprotective 
effect exists. 
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Fig. 2. Percentage change in mean arterial pressure as a function of baseline values during ischemia nd 
reperfusion. 
Table II. Mean arterial pressures and heart rates during baseline, occh~sion, and reperfusion 
Time after ligation (ram) Time after reperfusion (rain) 
Group Baseline 15 30 45 60 75 90 120 15 30 
Mean arterial pressure (mm Hg) 
C 103-+14 100-+15 110±14 110±10 111-+14 104±15 102_+14 97 + 13 89-+8 83-+3 
E 106-+5 94-+12 93±10 93±7 94-+6 94±5 95-+6 97"5  93-+6 94-+9 
B 98-+14 84 +16 81 +19 88+ 14 86"  14 84-+13 74± 15 75±9 73+8 65+5 
EB 88 -+ 12 51 + 12 74 ± 12 75 -+ 13 79 ± 15 73 -+ 16 69 + 17 93 ± 17 82 ± 17 68 -+ 21 
Heart rate (beats/rain) 
C 136_+13 134_+14 156±10 143_+11 141_+8 145±9 142+8 139± 12 137 + 13 141+ 15 
E 148-+ 14 117±13 115±12 111_+ 11 107±10" 109_+12 108 +9 110±8 103±5 103±5 
B 143±12 141± 12 141-+14 156± 13 141_+26 16029 173--6 168_+9 168± 11 185+_45 
EB 134±5 112_+5 119±7 123±9 125_+9 134± 14 132_+10 136± 13 144 +13 143± 16 
Values represent mean -+ standard error of the mean. 
*p < 0.05 vs control by analysis of variance. 
tp < 0.001 vs control by analysis of variance. 
We chose percutaneous cannulation of the arte- 
rial and venous system because traditional cardio- 
pulmonary bypass necessitates a major surgical pro- 
cedure with cannulation of the great vessels in the 
chest. 5 This is a time-consuming technique that 
requires pecialized equipment and training to per- 
form. In an effort to improve implementation of 
cardiopulmonary bypass in the setting of acute 
cardiac situations, percutaneous access is desirable. 
Although previous studies have evaluated the car- 
dioprotection associated with /3-blockers or percu- 
taneous cannulation to stabilize systemic hemody- 
namic and perfusion requirements, these treatments 
have not been investigated in combination. 5" 6, 9-11 
Our study was directed at evaluating the use of 
percutaneous cannulation of the arterial and venous 
system to resuscitate, stabilize, and support the 
patient--and possibly to reduce infarct size--and to 
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combine these benefits with the pharmacologic ben- 
efits of /3-blockade. In addition to its role for 
hemodynamic support, cardiopulmonary bypass has 
been used in several experimental models to MVo2 
and infarct size. Although several studies have dem- 
onstrated decreases in MVo2, significant increases 
have also been observed. 39-41 The greatest benefit 
from cardiopulmonary bypass has been shown with 
pulsatile perfusion systems, with either pulsatile 
bypass or a combination of nonpulsatile bypass with 
an intraaortic balloon pump. 1'6 We did not use 
pulsatile assist in this study because currently avail- 
able pulsatile bypass devices are not commercially 
available and are cumbersome to work with. 
In our study, we were able to demonstrate a 
reduction in infarct size with the use of esmolol plus 
percutaneous cardiopulmonary bypass (Table I). 
We did not attempt to delineate the mechanism by 
which this myocardial salvage occurred, but we did 
observe that during the combination of esmolol and 
bypass mean arterial pressure was reduced from 
control values throughout he ischemic period, while 
heart rate remained unchanged. This observation 
supports the concept hat the beneficial combination 
of esmolol with percutaneous bypass is from the 
reduction in afterload and protection from reflex- 
mediated increases in pressure and heart rate, 
thereby resulting in a lower myocardial energy ex- 
penditure during ischemia and thus leading to a 
smaller infarct. 
Conclusion 
The combination of ultra-short acting/3-blockers 
with cardiopulmonary bypass is theoretically attrac- 
tive because it provides a way of reducing myocar- 
dial damage during periods of ischemia while pro- 
viding mechanical circulatory assist to aid in 
resuscitation and circulatory support. Our experi- 
mental experience demonstrates a significant reduc- 
tion in extent of infarction when these modalities 
are combined. This combined approach of bypass 
and/3-blockade appears to be a promising area for 
further research, with important clinical ramifica- 
tions. 
We appreciate the helpful suggestions of our statisti- 
cian, C. Chen, PhD. 
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